Floatz logo

TAMOXIFEN

Breast Atypical Lobular Hyperplasia

Dana-Farber Cancer InstituteSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Breast Atypical Lobular Hyperplasia cohort.

Asset / SponsorPhaseRating
Ruxolitinib
Julie Nangia
Phase 2B
4-hydroxytamoxifen
Mayo Clinic
Phase 2CCC
EXEMESTANE
Dana-Farber Cancer Institute
Phase 2CCC
som230
NYU Langone Health
Phase 1CC
Pasireotide
NYU Langone Health
Phase 1CC
Bexarotene
National Cancer Institute (NCI)
Phase 1CC

Same molecule, other indications

TAMOXIFEN is also rated in:

estrogen-receptor positive breast cancerDormant
BBB
Indicative ·
77 / 100
View asset →
breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →
invasive breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →